Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)
Conditions
Brief summary
Change from Baseline to Week 80 in the iADRS score.
Detailed description
1. Change from Baseline to Week 80 in the ADCS-iADL, ADAS-Cog13, CDR-SB, and MMSE., 2. Change from Baseline to Week 80 in QoL-AD, 3. Further Secondary, Clinical, Safety, Pharmacodynamic, Pharmacokinetics, Pharmacogenomic, Blood and CSF Biomarker and Exploratory Endpoints are visible in the study protocol., 4. OLE: Changes from Baseline to Week 104 and Week 132 for iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE as measured by delayed-start analysis.
Interventions
DRUGACU193 matching Placebo
DRUGACU193
Sponsors
Acumen Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline to Week 80 in the iADRS score. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change from Baseline to Week 80 in the ADCS-iADL, ADAS-Cog13, CDR-SB, and MMSE., 2. Change from Baseline to Week 80 in QoL-AD, 3. Further Secondary, Clinical, Safety, Pharmacodynamic, Pharmacokinetics, Pharmacogenomic, Blood and CSF Biomarker and Exploratory Endpoints are visible in the study protocol., 4. OLE: Changes from Baseline to Week 104 and Week 132 for iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE as measured by delayed-start analysis. | — |
Countries
France, Germany, Spain
Outcome results
None listed